DE GIORGI, UGO FEDERICO FRANCESCO
DE GIORGI, UGO FEDERICO FRANCESCO
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer
2021-01-01 Conteduca V.; Wetterskog D.; Gonzalez-Billalabeitia E.; Brighi N.; De Giorgi U.; Attard G.
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
2017-01-01 Iacovelli, Roberto*; Cossu Rocca, Maria; Galli, Luca; De Giorgi, Ugo; Sabbatini, Roberto; Santoni, Matteo; Mosca, Alessandra; Fornarini, Giuseppe; Massari, Francesco; Masini, Cristina; Bersanelli, Melissa; Biasco, Elisa; Lolli, Cristian; Guida, Annalisa; Berardi, Rossana; Terrone, Carlo; Pastorino, Alessandro; Ardizzoni, Andrea; Pinto, Carmine; Buti, Sebastiano; Nolè, Franco; Tortora, Giampaolo
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome
2021-01-01 Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavilla A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U.
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
2021-01-01 Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C.; De Giorgi U.
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
2020-01-01 Altavilla A.; Casadei C.; Lolli C.; Menna C.; Ravaglia G.; Gurioli G.; Farolfi A.; Brighi N.; Conteduca V.; Burgio S.L.; Schepisi G.; Rossi L.; Gargiulo S.; Lisotti I.; De Giorgi U.
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
2021-01-01 Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci F.; Paganelli G.; Marchetti P.; De Giorgi U.
Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress
2021-01-01 De Padova S.; Urbini M.; Schepisi G.; Virga A.; Meggiolaro E.; Rossi L.; Fabbri F.; Bertelli T.; Ulivi P.; Ruffilli F.; Casadei C.; Gurioli G.; Rosti G.; Grassi L.; De Giorgi U.
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy
2021-01-01 Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravaglia G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U.
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
2021-01-01 Conteduca V.; Scarpi E.; Farolfi A.; Brighi N.; Rossi L.; Gurioli G.; Lolli C.; Schepisi G.; Bleve S.; Gianni C.; Virga A.; Altavilla A.; Burgio S.L.; Menna C.; De Giorgi U.
Moving beyond parp inhibition: Current state and future perspectives in breast cancer
2021-01-01 Palleschi M.; Tedaldi G.; Sirico M.; Virga A.; Ulivi P.; De Giorgi U.
New prognostic biomarkers in metastatic castration-resistant prostate cancer
2021-01-01 Conteduca V.; Mosca A.; Brighi N.; de Giorgi U.; Rescigno P.
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
2021-01-01 Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lolli C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U.
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients
2021-01-01 Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U.
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome
2014-01-01 Sara Pignatta;Chiara Arienti;Wainer Zoli;Marzia Di Donato;Gabriella Castoria;Elisa Gabucci;Valentina Casadio;Mirella Falconi;Ugo De Giorgi;Rosella Silvestrini;Anna Tesei
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra.
2021-01-01 Caffo O, Frantellizzi V, Monari F, Galli L, Costa RP, Pinto C, Tucci M, Baldari S, Facchini G, Bortolus R, Alongi F, Alongi P, Donner D, Fanti S, Sbrana A, Morabito A, Masini C, Zichi C, Pignata S, Borsatti E, Salgarello M, Spada M, De Giorgi U, Lo Re G, Cortesi E, De Vincentis G.
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA
2021-01-01 Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; Lolli C.; De Giorgi U.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer | Conteduca V.; Wetterskog D.; Gonzalez-Billalabeitia E.; Brighi N.; De Giorgi U.; Attard G. | 2021-01-01 | EUROPEAN UROLOGY ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer | Iacovelli, Roberto*; Cossu Rocca, Maria; Galli, Luca; De Giorgi, Ugo; Sabbatini, Roberto; Santoni, Matteo; Mosca, Alessandra; Fornarini, Giuseppe; Massari, Francesco; Masini, Cristina; Bersanelli, Melissa; Biasco, Elisa; Lolli, Cristian; Guida, Annalisa; Berardi, Rossana; Terrone, Carlo; Pastorino, Alessandro; Ardizzoni, Andrea; Pinto, Carmine; Buti, Sebastiano; Nolè, Franco; Tortora, Giampaolo | 2017-01-01 | UROLOGIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome | Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavilla A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U. | 2021-01-01 | MOLECULAR ONCOLOGY | - | 1.01 Articolo in rivista | - |
| The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives | Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C.; De Giorgi U. | 2021-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer | Altavilla A.; Casadei C.; Lolli C.; Menna C.; Ravaglia G.; Gurioli G.; Farolfi A.; Brighi N.; Conteduca V.; Burgio S.L.; Schepisi G.; Rossi L.; Gargiulo S.; Lisotti I.; De Giorgi U. | 2020-01-01 | EXPERT OPINION ON PHARMACOTHERAPY | - | 1.01 Articolo in rivista | - |
| Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging | Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci F.; Paganelli G.; Marchetti P.; De Giorgi U. | 2021-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress | De Padova S.; Urbini M.; Schepisi G.; Virga A.; Meggiolaro E.; Rossi L.; Fabbri F.; Bertelli T.; Ulivi P.; Ruffilli F.; Casadei C.; Gurioli G.; Rosti G.; Grassi L.; De Giorgi U. | 2021-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy | Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravaglia G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | - |
| Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma | Conteduca V.; Scarpi E.; Farolfi A.; Brighi N.; Rossi L.; Gurioli G.; Lolli C.; Schepisi G.; Bleve S.; Gianni C.; Virga A.; Altavilla A.; Burgio S.L.; Menna C.; De Giorgi U. | 2021-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Moving beyond parp inhibition: Current state and future perspectives in breast cancer | Palleschi M.; Tedaldi G.; Sirico M.; Virga A.; Ulivi P.; De Giorgi U. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | - |
| New prognostic biomarkers in metastatic castration-resistant prostate cancer | Conteduca V.; Mosca A.; Brighi N.; de Giorgi U.; Rescigno P. | 2021-01-01 | CELLS | - | 1.01 Articolo in rivista | - |
| Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study | Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lolli C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients | Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U. | 2021-01-01 | INTERNATIONAL JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome | Sara Pignatta;Chiara Arienti;Wainer Zoli;Marzia Di Donato;Gabriella Castoria;Elisa Gabucci;Valentina Casadio;Mirella Falconi;Ugo De Giorgi;Rosella Silvestrini;Anna Tesei | 2014-01-01 | MOLECULAR AND CELLULAR ENDOCRINOLOGY | - | 1.01 Articolo in rivista | - |
| Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. | Caffo O, Frantellizzi V, Monari F, Galli L, Costa RP, Pinto C, Tucci M, Baldari S, Facchini G, Bortolus R, Alongi F, Alongi P, Donner D, Fanti S, Sbrana A, Morabito A, Masini C, Zichi C, Pignata S, Borsatti E, Salgarello M, Spada M, De Giorgi U, Lo Re G, Cortesi E, De Vincentis G. | 2021-01-01 | CANCER BIOTHERAPY & RADIOPHARMACEUTICALS | - | 1.01 Articolo in rivista | - |
| An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA | Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; Lolli C.; De Giorgi U. | 2021-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |